Media stories about Vertex Pharmaceuticals (NASDAQ:VRTX) have been trending somewhat positive on Tuesday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the pharmaceutical company an impact score of 46.2970198337158 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 151.06 on Tuesday. The company has a market capitalization of $38.08 billion, a price-to-earnings ratio of 145.11 and a beta of 1.73. Vertex Pharmaceuticals has a 52-week low of $71.46 and a 52-week high of $167.85. The stock has a 50 day moving average price of $153.82 and a 200 day moving average price of $138.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The firm had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. During the same quarter last year, the company posted $0.24 earnings per share. The business’s revenue was up 26.1% on a year-over-year basis. On average, equities analysts expect that Vertex Pharmaceuticals will post $1.62 earnings per share for the current year.

A number of equities analysts have recently commented on VRTX shares. Stifel Nicolaus lifted their target price on Vertex Pharmaceuticals from $130.00 to $154.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Zacks Investment Research upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a report on Tuesday, July 4th. BidaskClub cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 28th. J P Morgan Chase & Co set a $184.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, Raymond James Financial, Inc. upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 target price for the company in a report on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twenty-three have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $167.25.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/10/24/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-vertex-pharmaceuticals-vrtx-share-price.html.

In other Vertex Pharmaceuticals news, COO Ian F. Smith sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $155.61, for a total value of $330,671.25. Following the sale, the chief operating officer now owns 118,013 shares of the company’s stock, valued at approximately $18,364,002.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paul M. Silva sold 860 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $152.99, for a total value of $131,571.40. Following the completion of the sale, the senior vice president now directly owns 17,494 shares in the company, valued at approximately $2,676,407.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,748 shares of company stock worth $6,734,021. Corporate insiders own 1.80% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.